Type 1 Diabetes Mellitus Clinical Trials in New Haven, Connecticut

6 studies are recruiting for type 1 diabetes mellitus in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Type 1 Diabetes Extension Study

   This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long…

   Stage

   Not phased

   Ages

   8 to 35

   Site

   Yale University, New Haven, Connecticut

   Locations

   12 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT02734277 on ClinicalTrials.gov

2. A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

   This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenou…

   Stage

   Phase 3

   Ages

   1 to 25

   Site

   Yale University School of Medicine- Site Number : 8400005, New Haven, Connecticut

   Locations

   197 in total

   Run by

   Sanofi

   See if you can join NCT07088068 on ClinicalTrials.gov

3. Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

   This is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and will then be followed for at least 12-48 months a…

   Stage

   Phase 2

   Ages

   4 to 34

   Site

   Yale University, New Haven, Connecticut

   Locations

   6 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT07216391 on ClinicalTrials.gov

4. Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

   This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once eve…

   Stage

   Phase 2

   Ages

   8 to 45

   Site

   Yale University, New Haven, Connecticut

   Locations

   15 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT07142252 on ClinicalTrials.gov

5. INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

   INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to <18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of …

   Stage

   Phase 2

   Ages

   6 to 17

   Site

   Yale University, New Haven, Connecticut

   Locations

   10 in total

   Run by

   Mannkind Corporation

   See if you can join NCT07224321 on ClinicalTrials.gov

6. Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

   This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

   Stage

   Not phased

   Ages

   14 to 75

   Site

   Yale, New Haven, Connecticut

   Locations

   11 in total

   Run by

   Insulet Corporation

   See if you can join NCT07579702 on ClinicalTrials.gov